- Raffles Medical's share price has risen by 7% year-to-date, in anticipation of strong 2H22 earnings and a likely positive outlook for its China segment. We expect greater clarity on the sustainability of its margins and updates on the outlook for its China businesses when Raffles Medical announces FY22 results on 27 Feb.
- - Read this at SGinvestors.io -
Near-term cost headwinds could persist despite recent strong margins.
- Raffles Medical Group (SGX:BSL) reported better-than-expected margins for 9M22, as the drop in costs from COVID-19-related business was faster and higher than the decline in revenue. However, we maintain that labour constraints and higher costs (wages and energy) may negatively impact its current elevated margin. Other healthcare players in Singapore are reporting a similar trend on the cost front as well.
- - Read this at SGinvestors.io -
China’s reopening could boost medical tourism in Singapore...
- Read more at SGinvestors.io.
Shekhar Jaiswal RHB Securities Research | https://www.rhbgroup.com/ 2023-02-03
Read also RHB's most recent report:
2024-07-30 Raffles Medical - 1H24 Numbers Below Expectations.
Previous report by RHB:
2024-07-01 Raffles Medical - Lukewarm Investor Response.
Price targets by other brokers at Raffles Medical Target Prices.
Listing of research reports at Raffles Medical Analyst Reports.
Relevant links:
Raffles Medical Share Price History,
Raffles Medical Announcements,
Raffles Medical Dividends & Corporate Actions,
Raffles Medical News Articles
